Valuation
- Market cap
- 9,433,000
- Revenue TTM
- $3,030,000
- Net income TTM
- $-7,810,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -257.76%
- Debt to equity
- 0.00
Trading
- Volume
- 35,500
- Avg volume
- 6,094
- Day's range
- $4.33 – $4.69
- Shares out
- 2,060,000
- Stochastic %K
- 74%
- Beta
- 1.00
- Analysts
- —
- Price target
- $50.00
Company profile
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatri...
Show more
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objectively detect, stage, and monitor peripheral neuropathies. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 781 890 9989
- Website
- https://www.neurometrix.com
- Address
- 4B Gill Street, Woburn, United States
Latest news
No headlines yet.
